Long-Term Liabilities: The sum of all non-current liabilities.
Provectus Biopharmaceuticals, Inc. (PVCT) had Long-Term Liabilities of $0.12M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-1.31M |
|
-- |
|
-- |
|
$1.28M |
|
$-1.28M |
|
$-0.05M |
|
$-1.32M |
|
$-1.32M |
|
$-1.32M |
|
$-1.32M |
|
$-1.32M |
|
$-1.32M |
|
$-1.28M |
|
$-1.28M |
|
420.28M |
|
420.28M |
|
$0.00 |
|
$0.00 |
|
| Balance Sheet Financials | |
$0.28M |
|
$0.00M |
|
$0.14M |
|
$0.42M |
|
$6.47M |
|
$0.02M |
|
|
Long-Term Liabilities |
$0.12M |
$6.59M |
|
$-6.18M |
|
$-6.17M |
|
$-6.17M |
|
420.28M |
|
| Cash Flow Statement Financials | |
$-2.46M |
|
-- |
|
$2.04M |
|
$0.49M |
|
$0.07M |
|
$-0.42M |
|
$0.95M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.04 |
|
-- |
|
-- |
|
-0.00 |
|
-0.37 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-2.46M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
21.41% |
|
21.46% |
|
-315.22% |
|
21.55% |
|
$-0.01 |
|
$-0.01 |
|
$-0.01 |
|